1-甲基-3,4-二氢-1H-苯并[e][1,4]二氮杂卓-2,5-二酮 | 1133-42-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 中文名称: 1-甲基-3,4-二氢-1H-苯并[e][1,4]二氮杂卓-2,5-二酮
• 英文名称: 1-methyl-1,2,3,4-tetrahydro-3H-1,4-benzodiazepin-2,5-dione
• 英文别名: 1-methyl-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione；1-methyl-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione；1-methyl-3H-1,4-benzodiazepine-2,5(1H,4H)-dione；1-Methyl-1,2,3,4-tetrahydro-3H-1,4 benzodiazepin-2,5-dione；1-methyl-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione；1-methyl-3,4-dihydro-1,4-benzodiazepine-2,5-dione
• CAS: 1133-42-2
• 化学式: C₁₀H₁₀N₂O₂
• mdl: MFCD07492626
• 分子量: 190.202
• InChiKey: MUESRUHFMTYDIT-UHFFFAOYSA-N

物化性质

• 熔点：
  192-193 °C
• 沸点：
  555.5±39.0 °C(Predicted)
• 密度：
  1.234±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  1-甲基-3,4-二氢-1H-苯并[e][1,4]二氮杂卓-2,5-二酮 在 吡啶 、 trifluoromethanesulfonic acid anhydride 、 乙硫醇 作用下， 以 ice water-filled Dewar 、 二氯甲烷 为溶剂， 生成 1,3-dihydro-5-(ethylthio)-1-methyl-2H-1,4-benzodiazepin-2-one
  参考文献：
  名称：

  Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds

  摘要：

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。

  公开号：

  US06528505B1
• 作为产物：
  描述：

  2-[(2-Bromoacetyl)-methylamino]benzoic acid 在 氨 作用下， 以 甲醇 为溶剂， 生成 1-甲基-3,4-二氢-1H-苯并[e][1,4]二氮杂卓-2,5-二酮
  参考文献：
  名称：

  A new series of potent benzodiazepine γ-secretase inhibitors

  摘要：

  A new series of benzodiazepine-containing gamma-secretase inhibitors with potential use in the treatment of Alzheimer's disease is disclosed. Structure-activity relationships of the pendant hydrocinnamate side-chain which led to the preparation of highly potent inhibitors are described. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00909-5

文献信息

• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020045747A1

  公开（公告）日：2002-04-18

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
• Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase
  申请人：Forum Pharmaceuticals, Inc.

  公开号：US20170000749A1

  公开（公告）日：2017-01-05

  This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

  这份披露涉及用于抑制组蛋白去乙酰化酶和治疗认知障碍或缺陷的化合物。更具体地，该披露提供了公式（I）的化合物 其中 Q、J、L和Z如规范中所定义。
• Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：Athena Neurosciences, Inc.

  公开号：US06506782B1

  公开（公告）日：2003-01-14

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性地治疗阿尔茨海默病的方法。
• Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：Elan Pharmaceuticals, Inc.

  公开号：US06509331B1

  公开（公告）日：2003-01-21

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性地治疗阿尔茨海默病的方法。
• Benzodiazepine derivatives
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US05556969A1

  公开（公告）日：1996-09-17

  Compounds of the formula (I): ##STR1## wherein R.sub.1 is hydrogen or specified optionally substituted alkyl, R.sup.2 is specified optionally substituted phenyl or pyridyl, x is 0, 1, 2 or 3, R.sup.3 is a specified alkyl, halo or amino and R.sup.4 is specified cycoalkyl or bicycloalkyl; and salts and prodrugs thereof, are useful as antagonists of cholecystokin and gastrin receptors.

  公式(I)的化合物：##STR1## 其中R1是氢或指定的可选取代烷基，R2是指定的可选取代苯基或吡啶基，x是0、1、2或3，R3是指定的烷基、卤素或氨基，R4是指定的环烷基或双环烷基；以及它们的盐和前药，可用作胆囊激肽和胃泌素受体的拮抗剂。

表征谱图